• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group.

作者信息

Ohki Kentaro, Butler Ellie R, Kiyokawa Nobutaka, Hirabayashi Shinsuke, Bergmann Anke K, Möricke Anja, Boer Judith M, Cavé Hélène, Cazzaniga Giovanni, Yeoh Allen Eng Juh, Sanada Masashi, Imamura Toshihiko, Inaba Hiroto, Mullighan Charles G, Loh Mignon L, Norén-Nyström Ulrika, Shih Lee-Yung, Zaliova Marketa, Pui Ching-Hon, Haas Oskar A, Harrison Christine J, Moorman Anthony V, Manabe Atsushi

机构信息

Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.

Leukaemia Research Cytogenetics Group, Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

出版信息

Leukemia. 2023 Jan;37(1):212-216. doi: 10.1038/s41375-022-01737-4. Epub 2022 Oct 29.

DOI:10.1038/s41375-022-01737-4
PMID:36309560
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9883149/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48da/9883149/2c9257a763e5/41375_2022_1737_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48da/9883149/2c9257a763e5/41375_2022_1737_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48da/9883149/2c9257a763e5/41375_2022_1737_Fig1_HTML.jpg

相似文献

1
Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group.伴有MEF2D重排的B细胞前体急性淋巴细胞白血病的临床特征及预后：莱尼亚诺儿童急性淋巴细胞白血病工作组的一项回顾性研究
Leukemia. 2023 Jan;37(1):212-216. doi: 10.1038/s41375-022-01737-4. Epub 2022 Oct 29.
2
Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group.伴有ZNF384重排的B淋巴细胞白血病的临床特征与预后：莱尼亚诺儿童白血病工作组的回顾性分析
Leukemia. 2021 Nov;35(11):3272-3277. doi: 10.1038/s41375-021-01199-0. Epub 2021 Mar 10.
3
MEF2D-BCL9 B-Lymphoblastic Leukemia Blast Morphology Does Not Always Mimic Mature B-Cell Leukemia.MEF2D-BCL9 型 B 淋巴母细胞白血病原始细胞形态并不总是类似于成熟 B 细胞白血病。
J Pediatr Hematol Oncol. 2021 Apr 1;43(3):112-113. doi: 10.1097/MPH.0000000000002009.
4
[Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].[伴有ZNF384和MEF2D重排的儿童B淋巴细胞白血病的临床特征与预后]
Rinsho Ketsueki. 2023;64(7):633-638. doi: 10.11406/rinketsu.64.633.
5
Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions.伴有MEF2D融合的成人B细胞急性淋巴细胞白血病患者的预后及分子可测量残留病监测
Hematol Oncol. 2023 Aug;41(3):594-597. doi: 10.1002/hon.3114. Epub 2022 Dec 19.
6
The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009.第十一届国际儿童急性淋巴细胞白血病研讨会报告：意大利蓬泰迪莱格诺，2009 年 5 月 6-7 日。
Leukemia. 2009 Dec;23(12):2318-24. doi: 10.1038/leu.2009.211. Epub 2009 Nov 5.
7
Clinical and molecular characteristics of fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in gene fusion.儿童融合阳性 B 细胞前体急性淋巴细胞白血病的临床和分子特征，包括一种导致基因融合的新型易位。
Haematologica. 2019 Jan;104(1):128-137. doi: 10.3324/haematol.2017.186320. Epub 2018 Aug 31.
8
MEF2D-rearranged acute lymphoblastic leukemia resembles Burkitt lymphoma/leukemia.MEF2D重排的急性淋巴细胞白血病类似于伯基特淋巴瘤/白血病。
Ann Hematol. 2020 Jan;99(1):185-188. doi: 10.1007/s00277-019-03857-x. Epub 2019 Nov 28.
9
The Eighth International Childhood Acute Lymphoblastic Leukemia Workshop ('Ponte di legno meeting') report: Vienna, Austria, April 27-28, 2005.第八届国际儿童急性淋巴细胞白血病研讨会（“蓬特雷尼亚戈会议”）报告：奥地利维也纳，2005年4月27 - 28日。
Leukemia. 2006 Jan;20(1):9-17. doi: 10.1038/sj.leu.2404016.
10
Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL.融合基因驱动 B-ALL 中的前 B 细胞受体信号。
Blood Cancer Discov. 2020 Jun 22;1(1):18-20. doi: 10.1158/2643-3249.BCD-20-0078. eCollection 2020 Jul.

引用本文的文献

1
Challenging Conventional Diagnostic Methods by Comprehensive Molecular Diagnostics: A Nationwide Prospective Comparison in Children With ALL.综合分子诊断对传统诊断方法的挑战：儿童急性淋巴细胞白血病的全国前瞻性比较
JCO Precis Oncol. 2025 Feb;9:e2400788. doi: 10.1200/PO-24-00788. Epub 2025 Feb 28.
2
Unraveling the Genetic Heterogeneity of Acute Lymphoblastic Leukemia Based on NGS Applications.基于二代测序技术应用解析急性淋巴细胞白血病的遗传异质性
Cancers (Basel). 2024 Nov 26;16(23):3965. doi: 10.3390/cancers16233965.
3
Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements.
具有 MEF2D 融合的急性 B 细胞淋巴母细胞白血病的遗传和临床特征及两种新的 MEF2D 重排的报告。
Ann Hematol. 2024 Oct;103(10):4155-4161. doi: 10.1007/s00277-024-05868-9. Epub 2024 Jul 11.
4
Genetic alterations in lymphoblastic leukaemia.淋巴细胞白血病中的基因改变。
Med Genet. 2024 Mar 6;36(1):39-45. doi: 10.1515/medgen-2024-2007. eCollection 2024 Apr.
5
Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia.高危儿童急性淋巴细胞白血病的生物标志物
Cancers (Basel). 2024 Feb 21;16(5):858. doi: 10.3390/cancers16050858.
6
Novel Biomarkers and Molecular Targets in ALL.急性淋巴细胞白血病的新型生物标志物和分子靶点。
Curr Hematol Malig Rep. 2024 Feb;19(1):18-34. doi: 10.1007/s11899-023-00718-3. Epub 2023 Dec 4.
7
Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL.推进诊断和治疗，实现儿童 ALL 的普遍治愈。
J Clin Oncol. 2023 Dec 20;41(36):5579-5591. doi: 10.1200/JCO.23.01286. Epub 2023 Oct 11.